Vicarious Surgical logoVicarious Surgical Inc CTO Sammy Khalifa sold 4,551 shares of Vicarious Surgical stock in a transaction on Monday, April 18. The shares were sold at an average price of US$4.18, for a total value of US$19,023.18. Following the completion of the transaction, the chief technology officer now owns 136,413 shares in the company, valued at approximately US$570,206.34. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
Sammy Khalifa also recently made the following trade(s):
On Thursday, April 14th, Sammy Khalifa sold 6,830 shares of Vicarious Surgical stock. The shares were sold at an average price of US$4.08, for a total value of US$27,866.40.
Shares of NYSE RBOT traded up $0.10 during mid-day trading on Tuesday, hitting US$4.40. 506,846 shares of the stock traded hands, compared to its average volume of 382,443. The company has a quick ratio of 28.56, a current ratio of 28.56 and a debt-to-equity ratio of 0.01. Vicarious Surgical Inc has a twelve month low of $3.98 and a twelve month high of US$15.79. The firm’s 50 day simple moving average is US$5.29.
Vicarious Surgical last released its quarterly earnings data on Thursday, March 3rd. The company reported (US$0.15) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of (US$0.11) by (US$0.04). On average, research analysts anticipate that Vicarious Surgical Inc will post -0.58 earnings per share for the current fiscal year.
Several equities analysts have recently issued reports on the company. Credit Suisse Group assumed coverage on Vicarious Surgical in a research note on Friday, January 7. They issued an “outperform” rating and a US$16.00 price target on the stock. Zacks Investment Research lowered Vicarious Surgical from a “buy” rating to a “hold” rating in a research note on Thursday, March 10. Finally, Piper Sandler lowered Vicarious Surgical from an “overweight” rating to a “neutral” rating and decreased their price target for the company from US$16.00 to US$7.00 in a research note on Friday, March 4. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of US$12.33.
A number of institutional investors and hedge funds have recently made changes to their positions in the business. Rothschild Investment Corp IL lifted its holdings in Vicarious Surgical by 108.0 per cent during the 1st quarter. Rothschild Investment Corp IL now owns 111,745 shares of the company’s stock worth US$566,000 after buying an additional 58,028 shares during the period. BlackRock Inc. lifted its holdings in Vicarious Surgical by 38,688.7 per cent during the 4th quarter. BlackRock Inc. now owns 817,277 shares of the company’s stock worth US$8,679,000 after buying an additional 815,170 shares during the period. Vident Investment Advisory LLC acquired a new position in Vicarious Surgical during the 4th quarter worth about US$11,399,000. Goldman Sachs Group Inc. acquired a new position in Vicarious Surgical during the 4th quarter worth about US$131,000. Finally, Oasis Management Co Ltd. acquired a new position in Vicarious Surgical during the 4th quarter worth about US$1,062,000. 82.48 per cent of the stock is currently owned by hedge funds and other institutional investors.
Vicarious Surgical Company Profile (Get Rating)
Vicarious Surgical Inc operates as a robotics technology company in the United States. The company focuses on developing and commercializing Vicarious System, a single-incision surgical robot that virtually transports surgeons inside the patient to perform minimally invasive surgery. Vicarious Surgical Inc was incorporated in 2014 and is headquartered in Waltham, Massachusetts.
